Cancers 2010, 2(1), 190-208; doi:10.3390/cancers2010190

Cancer Biomarkers: Are We Ready for the Prime Time?

1,email and 2,,* email
1 Institute of Cytology and Preventive Oncology, Division of Molecular Oncology, Noida, 201301, UP, India 2 Methods and Technologies Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institues of Health (NIH), 6130 Executive Blvd., Suite 5100, Bethesda, MD 20892-7324, USA Present address: Lab Molecular Biology, NCI, NIH, Bethesda, MD 20892, USA.
* Author to whom correspondence should be addressed.
Received: 20 February 2010; in revised form: 2 March 2010 / Accepted: 19 March 2010 / Published: 22 March 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
PDF Full-text Download PDF Full-Text [202 KB, uploaded 22 March 2010 16:26 CET]
Abstract: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In cancer, a biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis and epidemiology. These markers can be assayed in non-invasively collected biofluids. However, few cancer biomarkers are highly sensitive and specific for cancer detection at the present time. Consequently, biomarkers are not yet ready for routine use due to challenges in their clinical validation for early disease detection, diagnosis and monitoring to improve long-term survival of patients.
Keywords: biomarker; cancer; diagnosis; glycans; prognosis; validation

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Mishra, A.; Verma, M. Cancer Biomarkers: Are We Ready for the Prime Time? Cancers 2010, 2, 190-208.

AMA Style

Mishra A, Verma M. Cancer Biomarkers: Are We Ready for the Prime Time? Cancers. 2010; 2(1):190-208.

Chicago/Turabian Style

Mishra, Alok; Verma, Mukesh. 2010. "Cancer Biomarkers: Are We Ready for the Prime Time?" Cancers 2, no. 1: 190-208.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert